REG - PureTech Health PLC - Total Voting Rights

Puretech HealthAnnouncement

03/03/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250303:nRSC9471Ya&default-theme=true

RNS Number : 9471Y  PureTech Health PLC  03 March 2025

PureTech Health plc

 

Total Voting Rights and Share Capital - Month End Disclosure

 

Pursuant to DTR 5.6.1 of the Disclosure Guidance and Transparency Rules:

 

As at 28 February 2025 the issued share capital of PureTech Health plc
comprised 257,927,489 Ordinary Shares of one pence each. There were 17,738,040
shares held in treasury.

 

The total number of voting rights in PureTech Health plc is therefore
240,189,449.

 

This information may be used by shareholders in their calculations to
determine if they are required to notify their interest in, or a change to
their interest in, PureTech Health plc under the FCA's Disclosure Guidance and
Transparency Rules.

 

About PureTech Health

 

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including three that have been approved by the U.S. Food and Drug
Administration. A number of these programs are being advanced by PureTech or
its Founded Entities in various indications and stages of clinical
development, including registration enabling studies. All of the underlying
programs and platforms that resulted in this pipeline of therapeutic
candidates were initially identified or discovered and then advanced by the
PureTech team through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 Contact:

 Investor Relations

 IR@puretechhealth.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRPPUCCPUPAGAR